CRISPR THERAPEUTICS AG Operating Lease Right-of-Use Assets
CRISPR THERAPEUTICS AG (CRSP) had Operating Lease Right-of-Use Assets of $125.59 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-03
- 2026-06-30: Operating Lease, Right-of-Use Asset $125.59M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $128.67M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $131.72M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $134.66M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $125.59M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $128.67M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $131.72M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $134.66M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $137.64M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $140.28M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $143.46M 10-K · filed 2026-02-12 |
| 2024-09-30 | $146.29M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $148.54M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $151.25M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $153.99M 10-K · filed 2025-02-11 |
| 2023-09-30 | $156.22M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $159.35M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $153.35M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $156.92M 10-K · filed 2024-02-21 |
| 2022-09-30 | $161.51M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $166.74M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $171.54M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $174.46M 10-K · filed 2023-02-21 |
| 2021-09-30 | $175.13M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $179.38M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $50.13M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $50.87M 10-K · filed 2022-02-15 |
| 2020-09-30 | $38.45M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $39.30M 10-Q · filed 2020-07-27 |
| 2020-03-31 | $40.32M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $41.50M 10-K · filed 2021-02-16 |
| 2019-09-30 | $30.62M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $30.77M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $25.10M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |